
Clean Safety Profile


Buntanetap is orally available, well behaved, and well qualified as a candidate to treat neurodegeneration (AD, AD-DS and PD). Five clinical studies have been conducted with buntanetap, including three Phase 1 trials and two Phase 2 trials. The first was a single ascending dose (SAD) study in 72 healthy volunteers. The second was a multiple ascending dose (MAD) study in 48 healthy volunteers. The third was a proof of concept (POC) study in four mildly cognitive-impaired (MCI) patients. The most recent studies are two Phase 2 trials in 14 AD and 54 PD patients.
Clean safety profile up to 160mg, which is a dose that is expected to be about 10 times higher than the efficacious dose.
Details see: JPAD 2022 & Maccecchini 2012




Buntanetap, and where noted, buntanetap and/or ANVS405, reduced multiple neurotoxic proteins and therefore, rescued neuronal health and restored animals’ normal functions.
Lowered levels of neurotoxic proteins (ANIMAL):
Improved retrograde and anterograde axonal transport (ANIMAL):
Increased synaptic transmission in (ANIMAL):
Increased neurotransmitter release in (ANIMAL):
Increased levels of neurogenesis and BDNF in (ANIMAL):
Buntanetap and ANVS405 lowered inflammation in (MCI HUMANS and ANIMAL):
ANVS405 protected nerve cells in (ANIMAL):
In summary buntanetap improves or restores the affect function in seven different animal models:
In four models of memory and learning: AD mice [Teich at al. 2018]; Down syndrome mice [Chen et al. 2020]; stroke mice [Turcato et al 2018]; traumatic brain injury rats [Chesselet UCLA, submitted for publication]
In two models of movement disorder: PD mice [Kuo et al. 2019] and in FTD mice.
Finally, it protects the retina and eyesight in acute glaucoma rats.

